{"url":"https://newsforagent.com/news/2026-10-21/actinogen-medical-xanamiai-database-lock","markdown_url":"https://newsforagent.com/news/2026-10-21/actinogen-medical-xanamiai-database-lock.md","title":"Actinogen Medical locks XanaMIA data, results due November","headline":"Actinogen Medical enters database lock on 247-patient XanaMIA Alzheimer's trial","description":"Actinogen Medical has locked the XanaMIA trial database after 247 patients finished the 36-week study, with topline results due in mid-November.","section":"Research & Clinical Trials","published_at":"2026-10-21T02:00:35+00:00","modified_at":"2026-10-21T02:00:35+00:00","author":"News Desk","key_takeaways":["Actinogen Medical entered database lock for the XanaMIA trial after final patient visits, with results due mid-November.","The 36-week study tested 10mg of Xanamem once daily in 247 patients across Australia and the US.","CEO Dr Steven Gourlay said positive results would establish brain cortisol control as a treatable part of Alzheimer's biology."],"companies":[{"name":"Actinogen Medical","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0007uc4/actinogen-medical","website":"https://actinogen.com.au"}],"source":{"publisher":"EIN Presswire","title":"Actinogen Medical enters ‘database lock’ to process XanaMIA’ data and confirm findings","url":"https://www.einnews.com/article/951107950/live"},"other_sources":[],"tags":["Research & Clinical Trials","Actinogen Medical"],"body_markdown":"[Actinogen Medical](https://akta.pro/company-profiles/0007uc4/actinogen-medical) Ltd has entered database lock for its XanaMIA Alzheimer's disease trial, with results due in mid-November. The Australian clinical-stage company, which is developing the oral drug Xanamem, said the lock freezes trial data so analysis can begin. [EIN Presswire](https://www.einnews.com/article/951107950/live) carried the announcement.\n\n## Inside the XanaMIA Database Lock\n\nDatabase lock is the point at which trial data is locked to prevent further changes and allow analysis to begin. Final patient visits for XanaMIA are complete, and the company said results are set for release in mid-November.\n\nThe 36-week study tested Xanamem, an oral enzyme inhibitor designed to control elevated levels of the stress hormone cortisol in the brain. It involved 247 patients across Australia and the US. Researchers selected patients with elevated pTau181 using a blood test rather than more complex methods such as brain scans or biomarkers, a step the company said increases the trial's potential to detect an effect of Xanamem over the study period. Participants received 10mg of Xanamem or a placebo once daily, and researchers assessed the drug's ability to slow progression of Alzheimer's disease.\n\nActinogen CEO Dr Steven Gourlay said Xanamem has potential to become \"a transformational treatment option for patients and their families living with Alzheimers\". He also said: \"Positive results in November would clearly establish brain cortisol control as an important and treatable part of the biology of Alzheimer's disease\".\n\n## Actinogen's Funding and Trial Records\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Actinogen completed a $16.8 million capital raising in February 2026, made up of a $12.0 million placement and a $4.8 million share purchase plan, securing funding through the XanaMIA topline results expected in November 2026. The same records show the company received a positive interim analysis outcome from the XanaMIA Phase 2b/3 Data Monitoring Committee in February 2026, which recommended the trial continue without amendment. Enrollment of 247 participants across Australia and the United States was completed in December 2025, with the open-label extension commenced.\n\n## How Actinogen Reached the Readout\n\nIn July 2026, Actinogen said the fully enrolled Phase 2b/3 XanaMIA trial remained on schedule for topline results in November 2026, with an independent Data Monitoring Committee completing its third safety review and recommending the study continue without amendment, Yahoo reported. In August 2026, Proactiveinvestors reported that Actinogen was hosting a webinar on the future of Alzheimer's treatment as the readout approached. In September 2026, Proactiveinvestors reported that Actinogen secured $4.77 million in additional funding after Forrest Capital agreed to fully underwrite the exercise of its remaining unlisted options.\n\n## What Comes After Database Lock\n\nActinogen said in March 2026 it began the XanaMIA-OLE trial, an extension allowing former and current participants who completed the 36-week phase to receive active Xanamem daily for up to 25 months, with no placebo group, to assess long-term safety and tolerability.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}